Vesugen 20mg

Researchers comparing where to buy Vesugen for research should begin with identity documentation, lot-level COA records, and analytical testing rather than unsupported product claims. Vesugen is treated here as the KED/Lys-Glu-Asp research peptide; PubChem lists lysyl-glutamyl-aspartic acid under CID 87571363 with molecular formula C15H26N4O8 and molecular weight 390.39 g/mol [1], and published tripeptide literature links KED with Vesugen in model-specific contexts [2]. This Pure Lab Peptides guide keeps the discussion research-use-only and focuses on product-page review, literature interpretation, and laboratory documentation.

• Vesugen is associated with KED, also written as Lys-Glu-Asp; compare its compound identity across database records and batch documentation [1].
• Published literature discusses KED in short-peptide, endothelial-cell, cellular, and gene-expression models. Those findings remain model-specific [3] [6].
• HPLC can support peptide purity review, while LC-MS and mass spectrometry data can support identity review when the method and batch match the product documentation [11] [12].
• Product listing details such as 20mg or vial format should be read as catalog identifiers, not experimental instructions.
• RUO labeling identifies research-only materials and does not establish suitability for diagnostic or clinical applications [19] [20].
• The practical research-buyer question is whether the label, COA, testing record, storage documentation, and batch archive tell the same story.

Fast Answer: What Should Researchers Check Before They Buy Vesugen for Research?

Researchers evaluating where to buy Vesugen for research should first review the compound identity, batch-specific COA, peptide purity data, LC-MS identity support, lot traceability, and RUO labeling. Products discussed in this article are intended for laboratory research use only and are not intended for human or animal consumption. The safest commercial-research decision is documentation-led, not claim-led.

What Documentation Should Come First?

The first documents to compare are the product label, batch-specific certificate of analysis, lot number, test method summary, and storage record. ICH Q2(R2) explains that analytical procedure validation is meant to show that a method is fit for its intended analytical purpose, which is a useful framework for reviewing peptide testing records [16].

FDA guidance on analytical procedures also emphasizes documentation supporting identity, quality, purity, and related analytical attributes [18]. On a research product page, that translates into a simple question: can the documentation support what the listing says?

Why Should RUO Labeling Come Before Procurement?

RUO labeling sets the context for how product information should be read. FDA’s RUO guidance describes research-use-only labeling as appropriate when materials are in the laboratory research phase and not represented for diagnostic application [19].

The eCFR labeling provision for certain RUO-labeled IVD materials includes the phrase “For Research Use Only. Not for use in diagnostic procedures,” which illustrates why labeling clarity matters in regulated research contexts [20].

Vesugen Peptide Identity and Bioregulator Classification

Vesugen peptide identity starts with the KED sequence, written as Lys-Glu-Asp. PubChem identifies lysyl-glutamyl-aspartic acid as C15H26N4O8 with molecular weight 390.39 g/mol, giving researchers a neutral database anchor for molecular review [1].

The term bioregulator appears in short-peptide literature associated with Khavinson and colleagues.

What Is Vesugen in Research Literature?

Vesugen is generally discussed as a short synthetic peptide associated with KED. Published tripeptide literature describes KED/Vesugen in model-specific research involving endothelial and neuronal systems [2].

Other short peptide research has examined Vesugen and related peptides in tissue-specific cell culture models, including vascular endothelial cell literature focused on Ki-67 and MKI67 promoter-region modeling [3]. These are research contexts, not product-use claims.

How Does Lys-Glu-Asp Define the KED Tripeptide?

Lys-Glu-Asp describes a three-amino-acid sequence: lysine, glutamic acid, and aspartic acid. In one-letter notation, those residues form KED, which is why Vesugen research often uses KED as the compact sequence label [1].

For documentation review, the sequence matters because it links the product listing to molecular identity. It also gives the laboratory a way to compare the label, COA, and database record.

Why Does Short Peptide Classification Matter for Documentation?

Reviews of short-peptide literature discuss gene expression, cell differentiation, and model-specific biological processes [6] [7].

This classification provides literature context, not evidence of performance for a supplied product.

Vesugen Documentation for Laboratory Procurement

Evaluate Vesugen through traceable documentation. A listing such as Vesugen 20mg describes a catalog presentation; confirm the Vesugen/KED identity and listed amount against the batch records.

How Do Research Buyers Evaluate Listings Before Buying Vesugen for Research?

Research buyers evaluating where to buy Vesugen for research should compare identity fields first. The compound name, KED sequence, molecular formula, lot number, COA date, and test-method summary should align across the page and supporting records.

Analytical method quality also matters. ICH Q14 frames analytical procedure development as a science- and risk-based process for building procedures suitable for assessing material quality [17].

Why Should Vial Labeling Match Batch Records?

Vial labeling is a traceability checkpoint. If the label shows one lot identifier and the COA shows another, the documentation chain is unclear.

Good laboratory and research procurement practice depends on matching records. The label, product listing, COA, and supplier archive should point to the same batch-specific material.

Khavinson Peptide Literature and Bioregulator Context

The phrase Khavinson peptide is often used for short peptide literature connected with Vladimir Khavinson and collaborators. Reviews by Khavinson and colleagues discuss peptide regulation of gene expression and cell differentiation across several short peptide models [6] [7].

Where Does Khavinson Research Frame Short Peptides?

Khavinson-linked publications discuss short peptides through molecular, cellular, and gene expression models. For example, one systematic review summarizes peptide regulation of gene expression, while a separate review discusses short peptides in cell differentiation research [6] [7].

Those papers provide literature context. They do not replace batch-specific supplier documentation for any Pure Lab Peptides material.

Interpreting Attributed Research

KED literature includes molecular-genetic reviews, mesenchymal stem-cell culture studies, and induced-neuron models [5] [8] [9]. Interpret each within its experimental methods and findings.

Molecular and Cellular Context for Vesugen Research

Molecular context helps researchers verify whether a Vesugen product listing is internally consistent. Cellular context helps readers understand where published literature has placed KED.

A pathway or cell model explains research interest, not performance of a supplied material.

What Molecular Features Support Identity Review?

For Vesugen, key identity fields include the KED sequence, molecular formula C15H26N4O8, and molecular weight 390.39 g/mol [1]. These are useful cross-checks for labels, COAs, and analytical records.

LC-MS can add identity support by comparing observed mass-related signals with expected molecular information, while HPLC can help characterize separation and purity patterns [11] [12].

How Do Endothelial Cell Models Provide Research Context?

Vesugen research includes endothelial-cell models. A Springer-indexed paper reports studies of Vesugen and D-7 in vascular endotheliocyte cultures, including Ki-67 measurements and MKI67 promoter-region modeling [3].

That model-specific finding does not establish outcomes for a Pure Lab Peptides product.

Where Do Vascular Endothelial Concepts Fit in Literature?

KED/Vesugen research includes vascular wall and endothelial-cell contexts, as well as broader tripeptide models [2] [3]. Interpret the findings within the system studied.

Signal Pathway Research Context

Signal-pathway findings require the model type, measured endpoints, and evidence level for interpretation.

In Vesugen literature, signaling, gene-expression, and molecular-modeling findings concern the specific published research systems.

Why Is Pathway Relevance Not a Product Claim?

A pathway can be relevant to a research model without saying anything about how a listed material performs.

What Gene Expression Context Supports Literature Review?

Gene expression appears in short peptide literature as a research topic, including systematic review work and cell-culture studies involving KED and related peptides [6] [8]. These papers help define the literature map for Vesugen research.

They do not remove the need for batch-specific documentation. A research material still needs COA support, label consistency, and analytical review.

How Should Published Literature Be Read for Vesugen Peptide?

Published literature should be read in layers. Start with compound identity, then identify the model type, then evaluate what the study can and cannot support.

For Vesugen peptide, this prevents over-reading.

What Can Preclinical and In Vitro Models Clarify?

Preclinical and in vitro models can clarify how researchers studied KED in controlled settings. Literature includes organotypic culture research on Lys-Glu-Asp, vascular endothelial cell models, and specialized tripeptide model systems [3] [4] [9].

The RUO interpretation is narrow: these sources support literature context. They do not define a product application for a research-use-only listing.

Why Do Study Findings Need Source Quality Filters?

Source quality filters help separate peer-reviewed literature and official databases from marketing copy. A strong filter favors PubChem for compound identity, PubMed-indexed or peer-reviewed literature for model context, and official guidance for documentation principles [1] [6] [16].

Interpret each finding within the study design, measured endpoint, and experimental model.

How Do Translational Limits Shape RUO Interpretation?

Translational limits mean research findings should not be stretched beyond the model that produced them. FDA’s RUO guidance warns that labeling and surrounding materials can affect intended-use interpretation in regulated contexts [19].

Evidence Interpretation Framework for Laboratory Research

An evidence framework helps research buyers distinguish published findings from lot-specific analytical results.

Evidence Sources for Procurement Review

Procurement review draws on official compound databases, peer-reviewed model studies, analytical-method references, COAs, and RUO labeling. ICH Q14 and Q2(R2) provide method-development and method-validation concepts for analytical review [16] [17].

Compare identity, purity, method, lot, label, and archive records together.

Research Findings and Product Evidence

Research literature and product claims are different categories.

Some published literature outside the scope of RUO product use has examined compound classes in human study settings. That literature should not be interpreted as a use claim for research-use-only materials.

Interpreting Vesugen documentation and literature

Published Vesugen studies describe particular experimental materials and models. Evaluate the supplied lot separately through its COA, identity testing, purity method, and traceability records.

Common misunderstandings to correct: published literature is not product-use guidance; a purity value does not prove complete identity; pathway relevance is not a product claim; a COA should be batch-specific; and listing size is a catalog detail.

Documentation for Procurement Decisions

Documentation gives laboratory buyers batch-specific information; it does not establish suitability for non-research applications.

For Vesugen, review identity fields, COA details, HPLC data, LC-MS support, lot traceability, storage documentation, and the research-only statement.

COA Documentation for Vesugen Research Materials

A COA is useful when it is batch-specific, internally consistent, and method-aware. It should not be treated as a decorative trust badge.

For a Vesugen research material, the COA should support the identity and purity claims made by the listing. It should also match the lot and label records.

What Should a Certificate of Analysis Confirm?

A certificate of analysis should confirm key batch details: compound name, lot number, assay or purity result, test method, COA date, and laboratory source. ISO/IEC 17025 is a laboratory competence standard for testing and calibration labs, and ISO describes it as a way for laboratories to show they operate competently and generate valid results [21].

NIST also explains traceability through reference materials, certificates, and documented measurement relationships [22]. Those principles make COA review more than a single-number purity check.

How Do COA Details Support Batch-Specific Review?

Batch-specific review means the COA belongs to the material being evaluated. NIST describes certificates and reference material records as documents that accompany reference materials and support measurement traceability [22].

In practice, the buyer should compare lot number, date, compound identity, and method fields. If those details do not match, the documentation chain is weak.

Why Should COAs Align With Product Labels?

COAs and product labels should align because they are parts of the same traceability record. FDA RUO guidance also notes that labeling and related materials can be relevant to intended-use interpretation [19].

For a Vesugen vial, the label should not tell one story while the COA tells another. Research teams need consistent records.

Peptide Purity and Analytical Testing Considerations

Peptide purity and peptide identity are related but not identical. A clean chromatographic peak can support purity review, while identity confirmation needs method-specific evidence tied to the expected molecule.

A documentation-focused lab-test verification workflow can stay simple:

1. Verify the compound name, lot number, and label match across documents.
2. Review the batch-specific COA.
3. Check whether the purity testing method is listed.
4. Confirm whether identity testing is supported by LC-MS or another suitable analytical method.
5. Review chromatogram or mass data when available.
6. Check the COA date and lab source.
7. Record storage and handling requirements in a laboratory file.

How Does HPLC Support Peptide Purity Review?

HPLC is widely used in peptide analysis and purification because chromatographic separation can resolve peptide components under controlled conditions [11]. In COA review, HPLC data can support a peptide purity statement when the method and batch are clearly documented.

HPLC should not be treated as a complete identity record by itself. It is one part of the analytical file.

What Can LC-MS Confirm About Peptide Identity?

LC-MS combines liquid chromatography with mass spectrometry, allowing separation data to be paired with mass-related information [12]. Reviews of LC-MS workflows explain that mass spectrometry can support identification by analyzing ion signals and related parameters [14].

For Vesugen, LC-MS support should connect observed data to expected KED identity. The key is batch-specific documentation.

Why Do Mass Spectrometry Details Matter for Verification?

Mass spectrometry instruments sort ions based on mass-to-charge ratio, often written as m/z [15]. Retention time and mass-related signals can help researchers evaluate whether analytical data are consistent with the listed compound [12] [15].

These details should be reviewed alongside the COA, not isolated from it. Strong documentation ties the method, result, and lot together.

Lot Traceability and Supplier Documentation Review

Lot traceability helps connect a physical research material to the documents that describe it. That connection matters for research procurement because COAs, labels, and product records are only useful when they point to the same batch.

Documentation review should be boring in the best way. The same compound name, lot number, and identity fields should repeat across the record set.

Lot Records in Research Procurement

Lot records support traceability across receipt, storage, testing, and archive documents. NIST traceability guidance emphasizes documented measurement relationships and reference material records, which supports the broader idea of traceable laboratory documentation [22].

For Vesugen research, lot records help prevent document mismatch. They also make later review easier for laboratory teams.

Batch Documentation for Laboratory Review

Batch documentation should include the product listing, label, COA, analytical data summary, and storage notes. ISO/IEC 17025’s focus on competent testing and valid results is relevant when reviewing external laboratory documentation [21].

USP reference standard pages also frame reference materials around identity, purity, and quality-related use in testing contexts [23]. Those ideas support careful review of the records behind peptide materials.

Storage, Handling, and Lyophilized Powder Documentation

Storage and handling documentation should describe the conditions attached to the product record.

The goal is recordkeeping. A laboratory should be able to see what conditions the supplier lists, where those conditions appear, and whether the COA or label reinforces them.

Lyophilized Peptide Records for Stability Review

Lyophilized powder documentation matters because solid-state form and moisture control can influence stability discussions for peptide and protein materials. Clinical Chemistry recommendations for peptides used in mass spectrometry assays discuss peptide generation, quantification, storage, and handling as part of reliable assay practice [13].

Broader freeze-drying literature describes lyophilization as a drying technology used to support solid-state stability for biological materials [25]. Review supplier storage records independently for the supplied batch.

Storage Notes for Laboratory Use

Storage notes should be copied into laboratory records exactly as listed. USP <659> provides packaging and storage definitions, making it a useful reference for why storage language should be precise and documented [24].

For Vesugen peptide documentation, the key question is whether storage information appears consistently on the listing, label, and supporting records.

Final Review Before Researchers Buy Vesugen for Research

Before researchers buy Vesugen for research, the final review should be documentation-led.

Pure Lab Peptides supplies compounds for laboratory research use only. Products are not intended for human or animal consumption, diagnostic use, therapeutic use, clinical use, veterinary use, or as food, drugs, cosmetics, dietary supplements, or household products. Researchers are responsible for ensuring lawful, appropriate handling and use in accordance with applicable regulations and institutional guidelines.

Review the product-page documentation, COA details, and RUO labeling before evaluating this compound for laboratory research.

Supplier Documentation Matrix for Research Buyers

A simple documentation matrix can prevent scattered review. Compare the product listing, label, COA, analytical data, and batch archive side by side.

The matrix should answer five questions: Is the compound named consistently? Is KED/Lys-Glu-Asp shown correctly? Does the lot number match? Are HPLC and LC-MS records described clearly? Are storage notes documented?

Procurement Review Checklist for Vesugen Research

• Verify that Vesugen is labeled for research-use-only context.
• Review the batch-specific certificate of analysis.
• Confirm that peptide purity data are supported by analytical testing.
• Check that the lot number on the COA matches the product documentation.
• Compare Vesugen, KED, Lys-Glu-Asp, molecular weight, and sequence across records [1].
• Assess whether the page keeps literature context separate from product claims.
• Document storage conditions and supplier records in a laboratory file.

FAQs

What does research use only mean for Vesugen?

Research use only means Vesugen is intended solely for controlled laboratory research. Evaluate compound identity, research documentation, and batch records; this material is not intended as a consumer product.

Is Vesugen intended for human or animal consumption?

No, Vesugen is not intended for human or animal consumption. The relevant review points are product documentation, COA consistency, peptide identity, lot traceability, and research-use-only labeling.

What is Vesugen peptide bioregulator in research context?

Vesugen is discussed within short-peptide bioregulator research. It is a synthetic tripeptide associated with KED, also written as Lys-Glu-Asp, which supports identity comparison across documentation [1]. Research classification does not establish outcomes for a supplied product.

How should published literature about Vesugen be interpreted?

Published Vesugen studies provide model-specific research context. Preclinical experiments, in vitro models, transcriptional-regulation studies, and cellular processes help explain the research questions; interpret each finding within its methods and limitations.

What should researchers consider before they buy Vesugen for research?

Researchers should consider documentation before they buy Vesugen for research. Key review points include RUO labeling, batch-specific COA records, peptide purity data, identity testing, supplier documentation, and lot traceability. Product details should support research purposes and should not be read as applied guidance.

Why does a COA matter when reviewing Vesugen?

A COA connects the listed Vesugen compound to batch-specific documentation. Review lot number, identity fields, purity data, test method, and review date together with the product label and supplier records.

---

Researchers Cited in This Guide

The researchers listed below are cited for relevant published work. Their inclusion does not imply that they wrote, reviewed, or endorsed this guide or Pure Lab Peptides products.

Vladimir K. Khavinson

Author profile: RUDN Journal of Medicine Profile

Vladimir K. Khavinson’s publications address short peptides, gene expression, cell differentiation, and bioregulator models. They provide background for interpreting Vesugen as KED/Lys-Glu-Asp within broader short-peptide research.

Selected publications:

• Peptide Regulation of Gene Expression: A Systematic Review — Molecules, 2021. DOI: 10.3390/molecules26227053
• Peptide Regulation of Cell Differentiation — Stem Cell Reviews and Reports, 2020. DOI: 10.1007/s12015-019-09938-8

Natalia S. Linkova

Author profile: Google Scholar

Natalia S. Linkova’s coauthored publications cover short peptides, cellular models, and gene expression, including KED-related work. These studies describe controlled model systems, molecular markers, and research conditions relevant to interpreting the findings.

Selected publications:

• A publication examining Vesugen and D-7 in vascular endothelial cell research — Advances in Gerontology, 2015. DOI: 10.1134/S2079057015040116
• A publication examining short peptide gene-expression models in mesenchymal stem-cell culture — Molecular Biology Reports, 2020. DOI: 10.1007/s11033-020-05506-3

REFERENCES

1. National Center for Biotechnology Information. Lysyl-glutamyl-aspartic acid, PubChem CID 87571363. PubChem. Updated database record.
2. Khavinson V, Ilina A, Kraskovskaya N, Linkova N, Kolchina N, Mironova E, Erofeev A, Petukhov M. Tripeptide epigenetic-regulator study involving KED and EDR. Pharmaceuticals. 2021;14(6):515. DOI: 10.3390/ph14060515.
3. Khavinson VK, Tarnovskaya SI, Linkova NS, Guton EO, Elashkina EV. Vascular endothelial cell proliferation research involving Vesugen and D-7. Advances in Gerontology. 2015. DOI: 10.1134/S2079057015040116.
4. Chalisova NI, Lopatina NG, Kamishev NG, Linkova NS, Koncevaya EA, Dudkov AV, Kozina LS, Khavinson VK, Titkov YS. Lys-Glu-Asp organotypic culture research. Bulletin of Experimental Biology and Medicine. 2012;153:569–572. DOI: 10.1007/s10517-012-1768-7.
5. Khavinson VK, Lin’kova NS, Umnov RS. KED molecular-genetic review in neurogenesis-related research. Bulletin of Experimental Biology and Medicine. 2021;171:190–193. DOI: 10.1007/s10517-021-05192-6.
6. Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic Review. Molecules. 2021;26(22):7053. DOI: 10.3390/molecules26227053. PMID: 34834147.
7. Khavinson V, Linkova N, Diatlova A, Trofimova S. Peptide Regulation of Cell Differentiation. Stem Cell Reviews and Reports. 2020;16:118–125. DOI: 10.1007/s12015-019-09938-8. PMID: 31808038.
8. Ashapkin V, Khavinson V, Shilovsky G, Linkova N, Vanyushin B. Short peptide gene-expression study in mesenchymal stem-cell culture. Molecular Biology Reports. 2020;47:4323–4329. DOI: 10.1007/s11033-020-05506-3.
9. Kraskovskaya N, Linkova N, Sakhenberg E, Krieger D, Polyakova V, Medvedev D, Krasichkov A, Khotin M, Ryzhak G. Short peptide induced-neuron model study. International Journal of Molecular Sciences. 2024;25(21):11363. DOI: 10.3390/ijms252111363. PMID: 39518916.
10. Janssens Y, Wynendaele E, Vanden Berghe W, De Spiegeleer B. Peptides as epigenetic modulators: research review. Clinical Epigenetics. 2019;11:101. DOI: 10.1186/s13148-019-0700-7. PMID: 31300053.
11. Mant CT, Chen Y, Yan Z, Popa TV, Kovacs JM, Mills JB, Tripet BP, Hodges RS. HPLC Analysis and Purification of Peptides. Methods in Molecular Biology. 2007;386:3–55. DOI: 10.1007/978-1-59745-430-8_1. PMID: 18604941.
12. Lian W, et al. LC-MS/MS characterization workflow for synthetic peptides. Journal of the American Society for Mass Spectrometry. 2021. DOI: 10.1021/jasms.0c00479. PMID: 34110145.
13. Hoofnagle AN, Whiteaker JR, Carr SA, Kuhn E, Liu T, Massoni SA, et al. Recommendations for peptides used in mass spectrometry-based assays. Clinical Chemistry. 2016;62(1):48–69. DOI: 10.1373/clinchem.2015.250563. PMID: 26719571.
14. Karpievitch YV, Polpitiya AD, Anderson GA, Smith RD, Dabney AR. Liquid Chromatography Mass Spectrometry-Based Proteomics. The Annals of Applied Statistics. 2010;4(4):1797–1823. PMCID: PMC3095207.
15. Tuli L, Ressom HW. LC-MS Based Detection of Differential Protein Expression. Journal of Proteomics & Bioinformatics. 2009. PMCID: PMC2867618.
16. International Council for Harmonisation. ICH Q2(R2): Validation of Analytical Procedures. ICH Harmonised Guideline. 2023.
17. International Council for Harmonisation. ICH Q14: Analytical Procedure Development. ICH Harmonised Guideline. 2023.
18. U.S. Food and Drug Administration. Analytical Procedures and Methods Validation for Drugs and Biologics. FDA Guidance. 2015; web page updated 2020.
19. U.S. Food and Drug Administration. Distribution of In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only. FDA Guidance for Industry and FDA Staff. 2013; web page updated 2018.
20. Electronic Code of Federal Regulations. 21 CFR 809.10: Labeling for in vitro diagnostic products. U.S. Government Publishing Office. Current eCFR.
21. International Organization for Standardization. ISO/IEC 17025: Testing and calibration laboratories. ISO. 2017 standard overview.
22. National Institute of Standards and Technology. Metrological Traceability: Frequently Asked Questions and Resources. NIST. Updated resource.
23. United States Pharmacopeia. USP Reference Standards. USP official resource.
24. United States Pharmacopeia. USP <659> Packaging and Storage Requirements. USP–NF official preview chapter.
25. Chen Y, et al. Pharmaceutical protein solids: drying technology and solid-state characterization. AAPS PharmSciTech. 2021. PMCID: PMC8107147.

---

Research Disclaimer

This material is supplied strictly for in vitro laboratory research and is not for human or veterinary use. Published studies describe specific experimental materials, models, and methods; they do not establish the safety, efficacy, or suitability of this catalog product for non-research use. Review the original publications and the lot-specific analytical documentation independently.